logo
welcome
Reuters

Reuters

Antifungal drug developer F2G raises $100 million to fight 'superbugs', fund late-stage trial

Reuters
Summary
Nutrition label

80% Informative

F2G said on Thursday it has raised $100 million from investors including large drugmakers such as Johnson & Johnson and Pfizer .

The funding also includes investment from Novo Holdings that holds a controlling stake in Novo Nordisk .

The latest round would help the UK -based company complete a global late-stage study of its lead drug, olorofim.

The U.S. Food and Drug Administration rejected the drug last year , citing the need for more data after a mid-stage trial.

VR Score

91

Informative language

97

Neutral language

68

Article tone

formal

Language

English

Language complexity

54

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links